RILPIVIRINE (rilpivirine) by PharmaIN is emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets are a fixed-dose combination of the antiretroviral drugs ftc, rpv, and tdf [see ]. First approved in 2026.
Drug data last refreshed 19h ago
Emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets are a fixed-dose combination of the antiretroviral drugs FTC, RPV, and TDF [see ].
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine
Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
Worked on RILPIVIRINE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.